GLP1R and type 2 diabetes mellitus: Although SGLT2i and GLP-1 RAs do not yet have specific regulatory approval for PTDM, the substantial overlap between PTDM and type 2 diabetes in terms of metabolic derangements and cardiorenal risk provides a strong biological rationale for cautiously extrapolating the benefits of these agents to carefully selected kidney transplant recipients with PTDM.